Numedicus uses therapeutic switching to identify secondary uses for existing drugs in practically all areas.

There are various types of collaborator that we work with:

• University departments of pharmacology (for example) with academic discoveries of new uses for existing drugs, seeking strategic assistance with translation
• specialty pharma companies with existing products seeking indication expansion
• drug delivery companies seeking innovative new active products for incorporation into their devices or technology, with which new therapeutic uses often synergise
• mid-size pharmaceutical companies seeking new angles on their development portfolio or ideas for life cycle management, or a better understanding of the commercial potential for an in-licensing opportunity

Although therapeutic switching is not traditionally an area that large multinational companies might seek to work with Numedicus, there is increasing interest among such companies in the strategy.